The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing examining the impact of health care consolidation, which featured academic witnesses. In a letter submitted to the committee, AHA Executive Vice President Tom Nickels said, “If there was ever any doubt that the health care landscape is changing dramatically, one has to look no further than the recent announcements that CVS seeks to acquire Aetna; Amazon, Berkshire Hathaway and JP Morgan Chase & Co partnering on employee health care; and UnitedHealth Group embarking on a physician acquisition spree. The hospital field has long anticipated this disruption and has sought to participate by replacing an outdated ‘siloed’ health care system with a continuum of care to improve coordination and quality and reduce costs for patients. Building a continuum demands that providers are more integrated. This can take many forms, involving mergers with other hospitals, acquisition or employment of physicians and clinical integration, among other arrangements.” For more on the issue and AHA’s take, see today’s AHA Stat blog post.

Related News Articles

Letter
Public
AHA expresses support for the Maternal Health Accountability Act (S. 1112), as amended and passed by the Senate Health, Education, Labor and Pensions Committee…
Advisory
Member
This AHA Legislative Advisory offers a detailed summary of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for…
Letter
Public
AHA letter to the US Senate supporting Amendment #3787 to address ‘out-of-control cost’ of prescription drugs.
Letter
Public
AHA, health organizations letter to CMS regarding its decision to suspend billions of dollars in annual payments to insurers as required under the Affordable…
Advisory
Member
On June 6, President Trump signed into law the VA Maintaining Internal Systems and Strengthening Integrated Outside Networks Act of 2018, (S. 2372), known as…
Testimony
Public
AHA statement before the Senate Finance Committee on Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market.